Small molecule · Inhibitor · developed by Traws Pharma
TRX-100 is a capsule-formulated CEN inhibitor dosed once daily.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07371650 | Phase 2 | Influenza | Active not recruiting | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Influenza
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →